| HS Code | 221358 |
| Generic Name | Atorvastatin Calcium |
| Brand Names | Lipitor, Atorva, Atorlip |
| Drug Class | Statin (HMG-CoA reductase inhibitor) |
| Route Of Administration | Oral |
| Indications | Hypercholesterolemia, dyslipidemia, prevention of cardiovascular disease |
| Dosage Forms | Tablets |
| Strengths Available | 10 mg, 20 mg, 40 mg, 80 mg |
| Mechanism Of Action | Inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver |
| Half Life | Approximately 14 hours |
| Common Side Effects | Muscle pain, diarrhea, joint pain, nausea |
| Storage Conditions | Store below 25°C (77°F), protect from moisture |
| Prescription Status | Prescription only |
| Metabolism | Primarily hepatic, via CYP3A4 |
| Contraindications | Active liver disease, unexplained persistent liver enzyme elevations |
As an accredited Atorvastatin Calcium factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Atorvastatin Calcium tablets, 40 mg, are packaged in a sealed HDPE bottle containing 90 tablets with a child-resistant closure. |
| Container Loading (20′ FCL) | 20′ FCL can load about 12MT of Atorvastatin Calcium in 25kg fiber drums, with each drum securely palletized and shrink-wrapped. |
| Shipping | Atorvastatin Calcium is shipped in secure, tightly-sealed containers to prevent contamination and moisture exposure. Packaging meets international regulations for pharmaceutical chemicals. The product is typically transported at controlled room temperature, clearly labeled with hazard and handling information, and accompanied by all necessary documentation to ensure safe and compliant delivery. |
| Storage | Atorvastatin Calcium should be stored at controlled room temperature, typically between 20°C to 25°C (68°F to 77°F), and protected from moisture, heat, and light. The container should be tightly closed to prevent contamination and degradation. Keep away from incompatible substances, and store in a dry, well-ventilated area, out of reach of unauthorized personnel and children. |
| Shelf Life | Atorvastatin Calcium typically has a shelf life of 2 to 3 years when stored in a cool, dry place, away from light. |
As a manufacturer of Atorvastatin Calcium, we serve global pharmaceutical producers focusing on cardiovascular therapeutic segments. Below are defined downstream application scenarios, each reflecting standard-compliant industrial uses. Details cover regulatory adherence, recommended formulation ratios, process flow, and nature of finished products in each sector.
Pharmaceutical companies utilize Atorvastatin Calcium as the active pharmaceutical ingredient (API) in bulk tablet production for cholesterol management. The process requires precision blending with excipients such as microcrystalline cellulose, lactose monohydrate, and magnesium stearate, followed by direct compression or wet granulation according to master batch records. The downstream QC includes dissolution testing, impurity profile assessment, and compliance with stringent pharmacopoeial standards before batch release into the market as prescription drugs.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Finished dose manufacturers apply Atorvastatin Calcium in combination drug formulations targeting comorbidity management, such as hypertension and hyperlipidemia. The process requires compatibility studies and synchronized granulation with additional APIs, such as amlodipine besylate or other antihypertensive agents. Careful blending and analytical validation at each stage maintain product stability and therapeutic accuracy, with specific regulatory submissions necessary for combination approvals.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Generic drug manufacturers use Atorvastatin Calcium to produce cost-effective alternatives following patent expiry. These firms must match originator purity, physical-chemical characteristics, and dissolution profile, demanding exacting control over source material consistency. Production lines often run multi-ton batches under validated protocols, with comprehensive analytical support including HPLC profiling and residual solvent testing to ensure bioequivalence.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Contract manufacturers buy Atorvastatin Calcium in large drums for high-throughput blending and tabletting, serving multinational partners who require stringent process controls and transparent batch genealogy. These manufacturers operate under multiple jurisdictions, adapting formulation and release specifications as required by import market regulations. Integrated in-line testing and serialized packaging ensure high traceability and compliance.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Pediatric and geriatric medicine specialists integrate Atorvastatin Calcium into oral suspension and powder-for-reconstitution dosage forms, enabling precise dose titration for patients unable to swallow tablets. The process involves micronization of API, dispersion in carrier matrices, and stabilization against hydrolysis, with rigorous microbial and particulate monitoring during batch filling and lyophilization.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive Atorvastatin Calcium prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8618005193850
Email: sales8@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Working on Atorvastatin Calcium at scale has shown us that every batch starts with precision and ends with responsibility. Atorvastatin Calcium stands as a pharmaceutical ingredient designed with one purpose: managing cholesterol. The global need for statins continues to expand, and manufacturers face pressure on multiple fronts — not just to meet demand, but to ensure every kilogram meets stringent quality controls. From our daily experience in plant operations, small changes in process temperature, water content, or crystallization method can alter particle size and downstream tableting performance. A commitment to process control translates directly into patient safety.
Our Atorvastatin Calcium uses a model that caters to both generic and branded clients. Particle size influences blend uniformity and final tablet dissolution. Years of optimizing our crystallization and drying steps taught us that a narrower particle distribution reduces the risk of segregation. This subtle difference distinguishes material that processes on a high-speed tableting line without dusting issues or settling. Many end-users report fewer batch rejections when material features tight control on size specification.
Specifications shape outcomes, not just compliance. Our standard Atorvastatin Calcium model targets a purity of 99.5% and above by HPLC, with single-digits for residual solvents. Moisture content lands consistently below 0.5%, which protects stability during storage and transport. Achieving low ash levels protects against troublesome excipient interactions. We conduct metal analysis routinely, since regulatory agencies around the world monitor elemental impurities like lead and cadmium. Granule white color might seem routine, yet it often reveals batch-to-batch consistency. Uniform color suggests a tightly maintained process, where process deviations haven’t snuck through with heat stress or foreign contamination.
As active pharmaceutical ingredient (API) manufacturers, we focus on what’s critical to processors and patients. For example, the amorphous versus crystalline form of Atorvastatin Calcium offers considerable debate. We favor a crystalline form because it delivers better flow properties in automated lines, resulting in fewer stoppages and improved content uniformity for hard-pressed tablets. Feedback from tablet manufacturers showed that our crystalline product consistently outperformed more amorphous alternatives, which tend to clump and slow down automated feeding. Errors in crystalline form assignment often cause downstream regulatory hurdles, waste, and costly reprocessing. Our team continuously verifies solid-state purity using PXRD and DSC.
Every container of Atorvastatin Calcium reflects constant investment in people and technology. Contamination risks don’t just come from the outside world — they emerge from old pipes, uncalibrated mixers, or even dust in the packaging area. Our in-house team addresses risk mitigation through automated cleaning cycles and a robust environmental monitoring program. Investing in process analytical technology (PAT) allows real-time tracking of critical parameters, so we catch outliers before packaging. Over the years, incorporating inline IR spectroscopy has proven invaluable for detecting process upsets early, before they could reach a finished product.
One factor often overlooked by labs outside of manufacturing is scalability. Bench-scale batches offer textbook results, but scaling up by a factor of twenty can reveal new issues, such as incomplete dissolution or efficiency drops in spray-drying. We’ve learned that it’s not just about getting a certificate with “Pass” written on it. The real achievement is repeatability, shipment after shipment, in an environment where regulators, auditors, and customers sometimes visit on short notice.
Atorvastatin Calcium differs from other statin products by more than just its chemical formula. During development, we’ve observed that tablet manufacturers often favor Atorvastatin Calcium for its higher potency per milligram and its chemical stability under diverse storage conditions. Some statins, like simvastatin or pravastatin sodium, degrade quickly in the presence of heat or humidity. Atorvastatin Calcium’s resistance to hydrolysis simplifies warehousing and extends the reachable markets, especially in regions that lack reliable climate control.
Mechanistically, Atorvastatin Calcium acts as an HMG-CoA reductase inhibitor, lowering cholesterol by blocking a rate-limiting step in biosynthesis. Chemically, its calcium salt form offers high bioavailability and reliability in formulation, without introducing sodium load — a consideration for some patient populations. Processors find formulation more flexible, since calcium salts interact less aggressively with commonly used direct compression excipients. Feedback suggests tablets hold together better and disintegrate in predictable timeframes, which is a core concern for overseas regulatory submissions.
Different statins call for different processing environments. For example, rosuvastatin calcium typically demands even stricter humidity control, since it absorbs moisture rapidly, leading to sticky powders at scale. Atorvastatin Calcium’s higher melting point provides additional safety margin against unplanned equipment downtime or delays during granulation. Clients report fewer headaches on their production lines with this model because it tolerates slight fluctuations in humidity, which can never be perfectly controlled in every facility around the world.
Meeting the world’s growing need for Atorvastatin Calcium means constant focus on both volumes and compliance. It’s not enough to manufacture a high-quality product; the paperwork must back up every claim. Counterfeiting, parallel trading, and poor transportation sometimes disrupt global supply chains, putting patients at risk. With every export, we coordinate tightly with freight forwarders, document every step, and maintain traceable records for years after the product has left our plant gates.
Our regulatory scientists regularly navigate diverging standards from the FDA, EMA, and other authorities. These agencies might ask for additional impurity profiles or demand specific data on residual solvents that don’t always appear in other countries’ dossiers. Over the years, feedback from clients taught us that proactive engagement with regulators builds long-term confidence — they count on us not just for consistency at the drum level, but to provide documentation support during their post-market surveillance, too.
With intellectual property rules changing and markets opening up in regions such as Southeast Asia and Africa, we’ve built partnerships with trusted labs for before-shipment analysis, which avoids long customs delays. In the past, we’ve seen manufacturer’s material stuck at ports simply from a missing COA signature or missing minor contaminants report, and we treat these learnings as critical as any technical validation.
Direct engagement with research teams at wellness companies, generics producers, and hospital buyers continually shapes our approach. Several years ago, a leading pharmaceutical company shared their struggle with tablet hardness inconsistency, ultimately traced to Atorvastatin Calcium from multiple sources with varying bulk density values. We adjusted our process to ensure tighter control over tapped and untapped density. This seemed minor at the lab bench, but dramatically improved their batch reproducibility and enabled faster scale-up. Relationships like this, grounded in real daily troubleshooting, push our teams to solve root-cause problems instead of masking them with temporary fixes.
Manufacturers themselves tackle special challenges like fixed-dose combination tablets. Sometimes, Atorvastatin Calcium needs to blend with other APIs — like Amlodipine Besylate — which each bring distinct flow and mixing requirements. Our technical team works side-by-side with partners to perform blend testing, confirm compatibility, and offer formulation advice based on what we’ve seen succeed across other customer operations. No third-party laboratory can match the on-the-floor feedback loops we cultivate with repeated close-out meetings and case reviews.
Safety isn’t just a marketing term. In one case, a customer flagged visible discoloration in a packed batch. We traced it to a rare deviation in solvent recovery during crystallization, which had let trace impurities accumulate. We responded by revising our solvent monitoring cycles, preventing a recurrence not just for that client, but across every line producing Atorvastatin Calcium. Only direct manufacturers, with daily production records and long-tenured QC analysts, can pull off this level of corrective action before issues spread.
Every kilogram of Atorvastatin Calcium carries an environmental footprint, and real manufacturers face tough tradeoffs between efficiency and sustainability. We have a dedicated team working to reclaim solvents, reduce water use, and capture fine particulate emissions. What we do here ripples beyond our loading dock. We invested in high-efficiency scrubbers to prevent the release of volatile organic compounds, and we operate a closed-loop chill water system. By keeping heat and emissions in check, we keep local neighborhoods safer while running a more reliable operation.
Waste management, especially for spent solvents and washwaters, demands daily attention. Simple choices in solvent selection can dictate the feasibility of recycling or incineration. Our long-term partnerships with hazardous waste handlers stem from trust and routine compliance audits. Even with the most tightly run plant, occasional incidents — such as a small leak or misrouted wash stream — demand immediate response. The experience gained here plays into risk management planning for every new project we undertake, including future expansions of our Atorvastatin Calcium operations.
Regulators focusing more on environmental impact encourages us to innovate. We now work on process intensification strategies that lessen energy use and decrease total organic solvent consumption. These changes aren’t just about compliance or green branding. Lowering energy and solvent use reduces cost per batch and improves reliability, with fewer unplanned downtimes caused by waste buildup or utility failures. These lessons aren’t theoretical: every day on the shop floor, our operators suggest tweaks and test changes, refining old techniques to squeeze better performance and cleaner outcomes.
With cardiovascular diseases rising worldwide, more health systems start to see Atorvastatin Calcium as a pillar ingredient. A product in such high demand brings constant pressure. As a manufacturer, we must ensure regular supply in all market conditions, whether pandemic disruptions or spikes in raw material costs. Our procurement and logistics teams monitor the global supply chain in real-time, keeping safety stocks of key starting materials for Atorvastatin Calcium production.
Through difficult years, especially during the most recent health emergencies, we learned how fragile transportation can disrupt entire markets. Sudden export restrictions, border shutdowns, and labor shortages exposed weaknesses that we worked aggressively to address. By adding redundant suppliers and storage sites, as well as digital application tracking, we can move Atorvastatin Calcium fast, even across long distances, to our customers, many of whom supply public hospitals or rural clinics.
We’ve seen rising interest in customized particle grades and packaging formats. Some contract manufacturers now request Atorvastatin Calcium in pre-weighted sachets for direct loading into smaller mixers, reducing dust risks and operator exposure. Adjusting packaging for different climates, from high-humidity tropical areas to cold northern rail shipments, has made us rethink moisture barriers and labeling. These packaging innovations came directly from end-user requests, shared with us not in formal specifications, but in troubleshooting calls and site visits where our technical staff observed their daily regimen.
Improvements never plateau; markets raise their expectations year over year. Variability — even if within typical ranges — frustrates formulators and end-users trying to register multi-site filings. Our production staff maintain ongoing operator training, review deviation reports each morning, and keep root-cause thinking at the center of our quality culture. Only a manufacturing team — not a third-party trader — can truly absorb the value of these lessons and translate them to the next shift, the next order.
Auditors from overseas often walk our facilities, tracking each material lot, inspecting worker protocols, reviewing complaint records, and debating process detail with our chemists. These site reviews drive meaningful improvements, like rearranging drum loading procedures or updating gowning practices, because every detail matters. Our Atorvastatin Calcium buyers trust finished goods arrive exactly as tested, with supporting paperwork from the team that made it, not a faceless middleman.
Direct communication plays a key role here. Technical staff at customer plants need answers in real time — not in marketing powerpoint, but by phone, email, or even a video walk-through. Product recalls, though rare, shape our team’s habits to overcommunicate and document change points in the process. From feedback on annual process reviews, health authorities consistently highlight rapid, manufacturer-led response protocols as the gold standard.
Our work on Atorvastatin Calcium never stands still. New research on impurities and their pharmacological impact challenges us to refine analytical techniques. Fast-moving market trends, like the rise of fixed-dose combinations, demand constant adaptation in process and packaging. And at every stage, we take the lessons learned from the last batch, last shipment, and last customer call to make sure the next one is even better.
Working closely with scientists, engineers, and regulators keeps us grounded in practical reality. True value comes from a deep understanding of what each batch represents: not a commodity, but a core medicine that doctors rely on, governments track, and patients depend on every single day. Every kilogram, every shipment, every call for troubleshooting brings new challenges — and the ongoing opportunity to improve both product and process.